4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patientscardiovascular disorder, hypertensive disorder, vascular disorderActive, not recruitingPhase 22026-09-04NCT06857955
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorderActive, not recruitingPhase 32026-09-04NCT05739383
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseArterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorderActive, not recruitingPhase 32026-08-25NCT05030428
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.cardiovascular disorder, hypertensive disorder, vascular disorderRecruitingPhase 22026-07-30NCT07543120